Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 185Neoplasms 111Breast Neoplasms 100Colorectal Neoplasms 90Ovarian Neoplasms 72Neoplasm Metastasis 70Prostatic Neoplasms 67Multiple Myeloma 63Lung Neoplasms 59Squamous Cell Carcinoma of Head and Neck 47Endometrial Neoplasms 46Recurrence 45Pancreatic Neoplasms 43Leukemia, Lymphocytic, Chronic, B-Cell 38Small Cell Lung Carcinoma 37Stomach Neoplasms 36Carcinoma, Renal Cell 36Melanoma 33Leukemia, Myeloid, Acute 32Urinary Bladder Neoplasms 28Triple Negative Breast Neoplasms 28Lymphoma, Non-Hodgkin 27Parkinson Disease 4, Autosomal Dominant Lewy Body 26Head and Neck Neoplasms 25Lymphoma, Follicular 24Carcinoma, Hepatocellular 24Lymphoma, Large B-Cell, Diffuse 23Esophageal Neoplasms 22Advanced Solid Tumors 22Lymphoma 21

Interventions

Lutetium-177 1Lutetium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Gastroenteropancreatic Neuroendocrine Tumor × 30 days × Clear all
NCT05884255 2026-05-19

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
220 enrolled
EndocrineGastrointestinalNET

Advanced Gastroenteropancreatic Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡